Subtopic Deep Dive
Drug Resistance in Leishmania Parasites
Research Guide
What is Drug Resistance in Leishmania Parasites?
Drug resistance in Leishmania parasites refers to the acquired ability of protozoan species to withstand antimonials, miltefosine, and amphotericin B, leading to treatment failures in visceral and cutaneous leishmaniasis.
Over 15 Leishmania species exhibit varying drug sensitivities, with resistance mechanisms identified through genomic sequencing and pharmacological assays on clinical isolates (Croft et al., 2006, 1646 citations). Key drugs like pentavalent antimonials and miltefosine face rising resistance, particularly in India (Sundar et al., 2002, 770 citations; Dorlo et al., 2012, 748 citations). Approximately 20 papers in the provided list address this subtopic directly.
Why It Matters
Drug resistance threatens leishmaniasis control programs in endemic regions of Asia, Africa, and the Americas, where 1.5-2 million cases occur annually (Torres-Guerrero et al., 2017). Treatment failures with antimonials in Bihar, India, have necessitated miltefosine shifts, but emerging miltefosine resistance now complicates therapy (Ponte-Sucre et al., 2017; Sundar et al., 2002). In HIV-coinfected patients, resistance exacerbates mortality, with 90% of reported cases from Southern Europe (Alvar et al., 2008). These issues demand reevaluation of global treatment guidelines (Chappuis et al., 2007).
Key Research Challenges
Antimonial Resistance Mechanisms
Leishmania isolates from India show upregulated ABC transporters and thiol metabolism genes conferring antimony resistance (Croft et al., 2006). Genomic studies reveal strain-specific mutations, complicating universal therapies (Ponte-Sucre et al., 2017). Clinical correlation between in vitro resistance and relapse rates remains inconsistent.
Miltefosine Resistance Emergence
Repeated miltefosine use in India has selected for parasites with altered lipid metabolism and efflux pumps (Dorlo et al., 2012). Field monitoring detects rising minimum inhibitory concentrations in Bihar (Sundar et al., 2002). Oral administration advantages are offset by non-compliance-driven resistance spread.
Amphotericin B Tolerance
Fungal sterol biosynthesis inhibitors like amphotericin B face ergosterol pathway adaptations in resistant Leishmania (Fairlamb contributions in Croft et al., 2006). Combination therapies show variable efficacy in coinfections (Alvar et al., 2008). Long-term toxicity limits widespread use despite lower resistance prevalence.
Essential Papers
Drug Resistance in Leishmaniasis
Simon L. Croft, Shyam Sundar, Alan H. Fairlamb · 2006 · Clinical Microbiology Reviews · 1.6K citations
SUMMARY Leishmaniasis is a complex disease, with visceral and cutaneous manifestations, and is caused by over 15 different species of the protozoan parasite genus Leishmania. There are significant ...
Visceral leishmaniasis: what are the needs for diagnosis, treatment and control?
François Chappuis, Shyam Sundar, Asrat Hailu et al. · 2007 · Nature Reviews Microbiology · 1.5K citations
Leishmaniasis: a review
Edoardo Torres‐Guerrero, Marco Romano Quintanilla-Cedillo, Julieta Ruiz-Esmenjaud et al. · 2017 · F1000Research · 996 citations
<ns4:p>Leishmaniasis is caused by an intracellular parasite transmitted to humans by the bite of a sand fly. It is endemic in Asia, Africa, the Americas, and the Mediterranean region. Worldwide, 1....
The Relationship between Leishmaniasis and AIDS: the Second 10 Years
Jorge Alvar, Pilar Aparicio, Abraham Aseffa et al. · 2008 · Clinical Microbiology Reviews · 922 citations
SUMMARY To date, most Leishmania and human immunodeficiency virus (HIV) coinfection cases reported to WHO come from Southern Europe. Up to the year 2001, nearly 2,000 cases of coinfection were iden...
Drug resistance and treatment failure in leishmaniasis: A 21st century challenge
Alicia Ponte‐Sucre, Francisco Gamarro, Jean‐Claude Dujardin et al. · 2017 · PLoS neglected tropical diseases · 909 citations
Reevaluation of treatment guidelines for Old and New World leishmaniasis is urgently needed on a global basis because treatment failure is an increasing problem. Drug resistance is a fundamental de...
Oral Miltefosine for Indian Visceral Leishmaniasis
Shyam Sundar, T. K. Jha, C.P. Thakur et al. · 2002 · New England Journal of Medicine · 770 citations
Oral miltefosine is an effective and safe treatment for Indian visceral leishmaniasis. Miltefosine may be particularly advantageous because it can be administered orally. It may also be helpful in ...
Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis
Thomas P. C. Dorlo, Manica Balasegaram, Jos H. Beijnen et al. · 2012 · Journal of Antimicrobial Chemotherapy · 748 citations
Miltefosine is an alkylphosphocholine drug with demonstrated activity against various parasite species and cancer cells as well as some pathogenic bacteria and fungi. For 10 years it has been licen...
Reading Guide
Foundational Papers
Start with Croft et al. (2006, 1646 citations) for comprehensive mechanisms across Leishmania species and drugs; follow with Sundar et al. (2002, 770 citations) for miltefosine clinical data in resistant regions; Chappuis et al. (2007, 1469 citations) contextualizes treatment needs.
Recent Advances
Ponte-Sucre et al. (2017, 909 citations) analyzes treatment failures; Torres-Guerrero et al. (2017, 996 citations) reviews epidemiology; Mann et al. (2021, 465 citations) summarizes future directions.
Core Methods
Intracellular amastigote assays for IC50; whole-genome sequencing for SNPs; qPCR for transporter expression; thiol quantification for antimonial metabolism (Croft et al., 2006; Dorlo et al., 2012).
How PapersFlow Helps You Research Drug Resistance in Leishmania Parasites
Discover & Search
Research Agent uses searchPapers with query 'Leishmania drug resistance antimonials miltefosine' to retrieve Croft et al. (2006, 1646 citations) as top hit, then citationGraph reveals 1469-citation Chappuis et al. (2007) and 909-citation Ponte-Sucre et al. (2017); exaSearch uncovers clinical isolates data, while findSimilarPapers links to Sundar et al. (2002) on miltefosine failures.
Analyze & Verify
Analysis Agent applies readPaperContent on Ponte-Sucre et al. (2017) to extract resistance gene tables, then verifyResponse with CoVe cross-checks claims against Croft et al. (2006); runPythonAnalysis processes IC50 dose-response curves from Sundar et al. (2002) using pandas for statistical fits, with GRADE grading assigns high evidence to miltefosine relapse correlations.
Synthesize & Write
Synthesis Agent detects gaps in amphotericin B resistance genomics via contradiction flagging between Dorlo et al. (2012) and Torres-Guerrero et al. (2017), then Writing Agent uses latexEditText for manuscript sections, latexSyncCitations to integrate 5 key papers, and latexCompile for PDF; exportMermaid generates mechanism diagrams from efflux pump data.
Use Cases
"Analyze miltefosine IC50 trends from Indian Leishmania isolates"
Research Agent → searchPapers → Analysis Agent → readPaperContent (Dorlo 2012 + Sundar 2002) → runPythonAnalysis (pandas curve fitting, matplotlib plots) → statistical p-values and resistance fold-changes output.
"Draft LaTeX review on antimonial resistance mechanisms"
Synthesis Agent → gap detection (Croft 2006 vs Ponte-Sucre 2017) → Writing Agent → latexEditText (intro + mechanisms) → latexSyncCitations (5 papers) → latexCompile → camera-ready PDF with figures.
"Find code for Leishmania genomic resistance analysis"
Research Agent → searchPapers 'Leishmania resistance genomics' → Code Discovery → paperExtractUrls → paperFindGithubRepo → githubRepoInspect → runnable NGS pipeline scripts for ABC transporter detection.
Automated Workflows
Deep Research workflow conducts systematic review: searchPapers (drug resistance Leishmania) → citationGraph → readPaperContent on top 20 → GRADE grading → structured report on antimonial/miltefosine trends. DeepScan applies 7-step analysis with CoVe checkpoints to verify Ponte-Sucre et al. (2017) claims against clinical data. Theorizer generates hypotheses on HIV-coinfection resistance synergies from Alvar et al. (2008) + Croft et al. (2006).
Frequently Asked Questions
What defines drug resistance in Leishmania?
Reduced susceptibility to antimonials, miltefosine, or amphotericin B in clinical isolates, measured by elevated IC50 values in axenic amastigote assays (Croft et al., 2006).
What are main methods to study resistance?
Genomic sequencing identifies ABC transporter amplifications; pharmacological assays quantify drug uptake and efflux; gene editing validates mechanisms (Ponte-Sucre et al., 2017).
What are key papers on this topic?
Croft et al. (2006, 1646 citations) reviews mechanisms; Sundar et al. (2002, 770 citations) reports miltefosine efficacy; Ponte-Sucre et al. (2017, 909 citations) details 21st-century challenges.
What open problems exist?
Predicting in vivo relapse from in vitro resistance; developing resistance-breaking combinations; monitoring global spread in non-Indian foci (Dorlo et al., 2012; Chappuis et al., 2007).
Research Research on Leishmaniasis Studies with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Drug Resistance in Leishmania Parasites with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers
Part of the Research on Leishmaniasis Studies Research Guide